MYSP-PI-2022-030

朱依諄


下載導師簡歷CV
Section 1: Personal Particulars

朱依諄
Zhu Yi Zhun
Professor
28827222
88972880
yzzhu@must.edu.mo
Rua Da Doca Seca, 55K, Tower 2, The Praia
Macau University of Science and Technology
MUST-SKL of Quality Research in Chinese Medicine
Avenida Wai Long, Taipa, Macau
https://www.must.edu.mo/images/FP/files/ZhuYiZhun.pdf

Research Project provided for Macao Youth Scholars Program:

血管炎症免疫的分子新机制及新药开发
New mechanisms and drug discovery of inflammation and immune response in vascular senescence
1007 药学
1008 中药学,1001 基础医学
Solid back ground in molecular pharmacology
PhD or M.D.
Dr. Zhu was awarded ‘Lee Kuan Yew’ Research fellowship from Singapore in 1998, ‘National Distinguished Young Scientist from Natural Science Foundation of China (NSFC) in 2008 and Chief Scientist of National Key Basic Research Program (973) and Chief-PI for the National Platform of Drug Discovery in 2009. Dr. Zhu further received National Award for Innovative Research Work of the Returnees in 2009 from the State Council and Magnolia Golden Award from Shanghai Government in 2019. Dr. Zhu was awarded Cheung Kong Chair Professorship in 2012 by the Ministry of Education, China. In 2014, Dr. Zhu was awarded ‘Health China’ top 10 figures of the year and Natural Science Research Award (ranked first among the Second Class of 3, top award of the year) from Macau in 2018. His research focuses on drug developments especially for heart and brain. The original research of motherwort for cardiovascular protection (transferred to the enterprise for 150 million RMB) received 2 clinical approvals for CFDA as a novel candidate drug and started clinical phase II trials. Phase I clinical trial as first-in-class will be started in US as well with the final approval by the FDA. In September 2012, the US ‘Science’ magazine reported that Professor Zhu was the one of the most successful Chinese returnees scientists (September 2, 2012, p. 1692). In 2017, the American Chemical Society's news journal ‘C&EN’ featured Professor Zhu's experience in drug development and praised him as one of the pioneers of life science research in China (April 3, 2017, 27-29).

Section 2: Research Interests and Grants

Cardiovascular Pharmacology Inflammation and immune response Drug discovery
15
82
12
近五年來承擔的重要科研項目清單:
1. 國家自然科學基金面上專案,81973320,Smyd3-PARP16軸調控血管衰老的作用及機制研究,2020-01至2023-12,55萬元 在研,主持
2. 澳門科學技術發展基金,FDCT-20-022-SP,大蒜來源的I類新藥ZYZ-802 治撩老年癡呆的成藥性研究和開發,2020-01至2023-01, 900萬元(澳門幣) 在研,主持
3. 澳門科學技術發展基金,0052/2020/A, 硫化氫在冠狀肺炎及其抗炎和免疫調節研究,2020-04至2021-04,42萬元(澳門幣)在研,主持
4. 澳門科學技術發展基金,0067/2018/A2 FDCT-19-026-SP,組蛋白甲基化酶SMYD3抑製劑的設計合成、抑制血管衰老作用及其分子機制研究. 2019-01至2022-01, 336.6萬元(澳門幣)在研,主持
5. 澳門科學技術發展基金,033/2017/AMJ FDCT-18-031-SP,益母草堿對血管重構的作用機制及其新型衍生物的設計與驗證,2018-10至2021-10,112.035萬元(澳門幣),在研,主持
6. 國家科技重大專項“重大新藥創制” 2017ZX09301002,益母草堿的產業化和臨床研究和開發,2017-10至2020-09, 398萬元,已結題,主持
7. 澳門科學技術發展基金, 055/2016/A2 FDCT-16-019-SP,硫化氫治療炎症性疾病的表觀遺傳學及靶分子研究. 2017-02至2020-02,271.37萬元(澳門幣), 已結題,主持
8. 澳門科學技術發展基金,039/2016/A,AMPK參與H2S對炎性鐵調素的抑制及用於炎症性貧血治療之研究 2017/03/30-2018/03/30,40.59萬元(澳門幣),已結題,主持
9. 國家自然科學基金面上專案,81573421,內源性硫化氫調節劑SPRC通過調控gp130- JAK-STAT3通路改善心肌重構,2016-01至2019-12,75萬元,已結題,主持
10. 國家自然科學基金重點專案,81330080,活性氣體分子H2S在心肌重構過程中的抗炎、免疫調節及機制研究,2014-01至2018-12,290萬元,已結題,主持